"The failure of Nilotinib to provide a clinically meaningful benefit in PD patients in two double-blind studies is discouraging, but may be explained by the fact that nilotinib does not accumulate in the brain at concentrations sufficient to inhibit c-Abl."

https://movementdisorders.onlinelibr...1002/mds.28858